Results 21 to 30 of about 261 (136)

Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer. [PDF]

Clin Transl Med
Lung cancer‐related changes in fragmentomic features were unevenly distributed across the genome, showing significant enrichment in epigenetically regulated regions of specific genes. The cfDNA fragmentomics‐based model demonstrated superior detection capability, especially for early‐stage lung cancer.
Wang Y, Guo Q, Huang Z, Song L, Zhao F, Gu T, Feng Z, Wang H, Li B, Wang D, Zhou B, Guo C, Xu Y, Song Y, Zheng Z, Bing Z, Li H, Yu X, Fung KL, Xu H, Shi J, Chen M, Hong S, Jin H, Tong S, Zhu S, Zhu C, Song J, Liu J, Li S, Li H, Sun X, Liang N.   +32 more
europepmc   +2 more sources

Cell-Free DNA Fragmentomics in Liquid Biopsy

Diagnostics, 2022
Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma cfDNA consists of a mixture of molecules originating from various bodily tissues.
Spencer C. Ding, Y.M. Dennis Lo
openaire   +3 more sources

Emerging frontiers of cell-free DNA fragmentomics

Extracellular Vesicles and Circulating Nucleic Acids, 2022
Analysis of cell-free DNA (cfDNA) in the blood has shown promise for monitoring a variety of biological processes. Plasma cfDNA is a mixture comprising DNA molecules released from various bodily tissues, mediated by characteristic DNA fragmentations occurring during cell death.
Hu, Xi, Ding, Spencer C., Jiang, Peiyong
openaire   +2 more sources

Epigenetic analysis of cell-free DNA by fragmentomic profiling

Proceedings of the National Academy of Sciences, 2022
Cell-free DNA (cfDNA) fragmentation patterns contain important molecular information linked to tissues of origin. We explored the possibility of using fragmentation patterns to predict cytosine-phosphate-guanine (CpG) methylation of cfDNA, obviating the use of bisulfite treatment and associated risks of DNA degradation.
Qing Zhou, Guannan Kang, Peiyong Jiang, Rong Qiao, W. K. Jacky Lam, Stephanie C. Y. Yu, Mary-Jane L. Ma, Lu Ji, Suk Hang Cheng, Wanxia Gai, Wenlei Peng, Huimin Shang, Rebecca W. Y. Chan, Stephen L. Chan, Grace L. H. Wong, Linda T. Hiraki, Stefano Volpi, Vincent W. S. Wong, John Wong, Rossa W. K. Chiu, K. C. Allen Chan, Y. M. Dennis Lo   +21 more
openaire   +2 more sources

At the dawn: cell-free DNA fragmentomics and gene regulation [PDF]

British Journal of Cancer, 2021
AbstractEpigenetic mechanisms play instrumental roles in gene regulation during embryonic development and disease progression. However, it is challenging to non-invasively monitor the dynamics of epigenomes and related gene regulation at inaccessible human tissues, such as tumours, fetuses and transplanted organs.
openaire   +2 more sources

Cell-Free DNA Fragmentomics: The Novel Promising Biomarker

International Journal of Molecular Sciences, 2023
Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry the genetic and epigenetic information of its origin tissues. However, cfDNA is the mixture of various cell fragments, and the efficient enrichment of cfDNA fragments with diagnostic value remains a great challenge for ...
Ting Qi, Min Pan, Huajuan Shi, Liangying Wang, Yunfei Bai, Qinyu Ge   +5 more
openaire   +2 more sources

Detection and characterization of lung cancer using cell-free DNA fragmentomes [PDF]

Nature Communications, 2021
AbstractNon-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection
Dimitrios Mathios, Jakob Sidenius Johansen, Stephen Cristiano, Jamie E. Medina, Jillian Phallen, Klaus R. Larsen, Daniel C. Bruhm, Noushin Niknafs, Leonardo Ferreira, Vilmos Adleff, Jia Yuee Chiao, Alessandro Leal, Michael Noe, James R. White, Adith S. Arun, Carolyn Hruban, Akshaya V. Annapragada, Sarah Østrup Jensen, Mai-Britt Worm Ørntoft, Anders Husted Madsen, Beatriz Carvalho, Meike de Wit, Jacob Carey, Nicholas C. Dracopoli, Tara Maddala, Kenneth C. Fang, Anne-Renee Hartman, Patrick M. Forde, Valsamo Anagnostou, Julie R. Brahmer, Remond J. A. Fijneman, Hans Jørgen Nielsen, Gerrit A. Meijer, Claus Lindbjerg Andersen, Anders Mellemgaard, Stig E. Bojesen, Robert B. Scharpf, Victor E. Velculescu   +37 more
openaire   +6 more sources

Polyadenylation ligation‐mediated sequencing (PALM‐Seq) characterizes cell‐free coding and non‐coding RNAs in human biofluids

Clinical and Translational Medicine, Volume 12, Issue 7, July 2022., 2022
PALM‐Seq simultaneously characterizes the abundance and molecular signature of cell‐free coding and non‐coding RNAs. The profiles and end motifs of cf‐mRNA and cf‐lncRNA can distinguish biofluids. Seminal plasma tends to retain longer fragments than other biofluids.
Zhongzhen Liu, Taifu Wang, Xi Yang, Qing Zhou, Sujun Zhu, Juan Zeng, Haixiao Chen, Jinghua Sun, Liqiang Li, Jinjin Xu, Chunyu Geng, Xun Xu, Jian Wang, Huanming Yang, Shida Zhu, Fang Chen, Wen‐Jing Wang   +16 more
wiley   +1 more source

Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond

Journal of Biomedicine and Translational Research, 2021
The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenues towards noninvasive prenatal testing (NIPT) for aneuploidies, hereditary DNA mutations and other pregnancy-related developmental disorders. Increasingly, cfDNA catches interest for its noninvasive screening value in other areas as well, including ...
Kavish Kohabir, Rob Wolthuis, Erik A. Sistermans   +2 more
openaire   +4 more sources

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection. [PDF]

Nat Rev Cancer
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use targeted tumour-specific mutations or methylation analyses.
Bruhm DC, Vulpescu NA, Foda ZH, Phallen J, Scharpf RB, Velculescu VE.   +5 more
europepmc   +4 more sources